Lunch and Learn on May 9 with Biointron: Accelerate Your Antibody Development!

Apr 25, 2024

Expert talks on antibody-drug conjugates (ADCs) and high-throughput antibody expression technology.

Posted by Biointron Biological

Interested in learning about the advancements in next-generation HTP antibody and antibody-drug conjugate (ADC) development in the biopharma industry? Look no further! We’re thrilled to announce a special Lunch & Learn session hosted by Biointron at MassBio, featuring our SVP of R&D, Lei Shi, PhD, and a special guest speaker, Victor Goldmacher. This is your chance to ask questions, share ideas, and make valuable connections with industry experts.

Unlocking Hidden Efficiencies: Accelerate Your Antibody Development with Biointron Insights 

Date: Thursday, May 9 at 12:30 PM

Location: MassBioHub, 700 Technology Square, 5th Floor, Cambridge, MA 02139

Free parking is available if registered before April 12, 2024

Event Agenda 

Sign Up: 12:30 PM – 1:00 PM

Biointron Intro & Expert Talks: 1:00 PM – 2:00 PM

Food, drinks, and snacks will be provided

Networking with Industry Peers: 2:00 PM – 3:00 PM

About the Speakers

Lei Shi, PhD, is the SVP of R&D at Biointron. Prior to that, he worked for a series of biotech companies, including Virtuoso Therapeutics, Zai Lab, and Bird Rock. He has also worked at J&J in antibody discovery technology and completed his postdoc study at MGH and Harvard Medical School.

Victor Goldmacher is an alumnus of Moscow State University. Following Postdoctoral training at MIT, focusing on Cell Biology, he took on a role as a junior faculty member at the Dana-Farber Cancer Institute and Harvard Medical School. Victor’s most notable professional tenure was at ImmunoGen, Inc., where, as Head of Cell Biology, he played a pivotal role in the discovery of three FDA-approved ADC therapies: Kadcyla, Sarclisa, and Elahere, and the discovery of two cell death suppressors of cytomegalovirus. Victor then transitioned to Forbius, Inc. as the Director of Discovery, a tenure highlighted by Forbius’s acquisition by Bristol Myers Squibb, driven by the promising clinical candidate, the tgf-beta trap. Currently, Victor is a co-founder and the Chief Scientific Officer at ImmuVia, Inc., where he is at the forefront of developing innovative ADC-mimetic bispecific antibodies for the treatment of cancer.

The title of his talk is ‘Advancements and Breakthroughs in Antibody-Drug Conjugates and ADC Mimetics‘.

Abstract: This presentation will provide a historical perspective on the development of Antibody-Drug Conjugates (ADCs) and ADC mimetics, with a focus on the advancements in protein design of antibody derivatives. We will explore the challenges faced by the early iterations of ADCs, delve into innovative strategies for their enhancement, and discuss the paradigm shift introduced by bypassing the need for internalization (the emergence of ADC mimetics). The talk will also highlight enhancing the payload delivery to lysosomes, setting a new standard in targeted therapy.

Space is limited, so reserve your spot here today. We look forward to seeing you there!

See all Member News